Perlecan is a heparan sulfate proteoglycan protein in the extracellular matrix that structurally and biochemically supports the cerebrovasculature by dynamically responding to changes in cerebral blood flow. These changes in perlecan expression seem to be contradictory, ranging from neuroprotective and angiogenic to thrombotic and linked to lipid retention. This review investigates perlecan's influence on risk factors such as diabetes, hypertension, and amyloid that effect Vascular contributions to Cognitive Impairment and Dementia (VCID). VCID, a comorbidity with diverse etiology in sporadic Alzheimer's disease (AD), is thought to be a major factor that drives the overall clinical burden of dementia. Accordingly, changes in perlecan expression and distribution in response to VCID appears to be injury, risk factor, location, sex, age, and perlecan domain dependent. While great effort has been made to understand the role of perlecan in VCID, additional studies are needed to increase our understanding of perlecan's role in health and in cerebrovascular disease. a Sperm, Enterokinase and Agrin fold with GAG and heparan sulfate (HS) attachment sites that has been proposed to facilitate the release of heparan binding growth factors in wound healing [33] [34] [35] . This domain has a distinct, perlecan specific protein motif that does not share homology with any other proteins [36] . Truncated perlecan DI, found in Hspg2 −/− or perlecan knock out mice, has been associated with complete loss of function, embryonic lethality (~E10-12), enlarged ventricles, smaller brains, and weakened vasculature leading to severe bleeding and heart malformations [24, 25, 37] . Rescuing this phenotype via cartilage-specific perlecan (Hspg2 −/− ; Col2a1-Hspg2 TG/− ) knock in [38] results in 50% more survivability at~E10-12 [39], normal cephalic development [39], intact BBB [40], but decreased neurogenesis [41], and endothelial [42] and pericyte [40] dysfunction following injury.
Extracellular Matrix and Perlecan
The basement membrane (BM) is a thin layer of extracellular matrices (ECMs) that anchors the epithelium (e.g., respiratory tract), mesothelium (e.g., peritoneal cavity), and endothelium (e.g., vasculature) to the underlying smooth muscle and connective tissue [1, 2] . This specialized form of ECM is a scaffolding of interwoven macromolecules and proteins that provide structural support, contribute to differentiation, and serve as a signaling platform (reviewed in [3] [4] [5] [6] ). This dynamic interface represents a delicate balance among protein synthesis, proteolysis, and metabolism [4, [7] [8] [9] , contributing to cellular plasticity and tissue specificity. The vascular BM not only mediates compartmentalization but also creates a selective barrier to infiltrating proteins and cells in parts of the body, such as the brain, sustaining blood-brain barrier (BBB) integrity [4, [7] [8] [9] . Ranging from 20 to 200 nm, the ECM consists of over 20 proteins, including a number of glycoproteins such as laminins, collagen IV, nidogens, and heparan sulfate proteoglycans (HSPG) (reviewed in [3] [4] [5] [6] ).
Perlecan is one of the most abundant heparan sulfate proteoglycans (HSPG) [10] , encoded by HSPG2 on chromosome 1 [11] [12] [13] . The role of perlecan has been studied in a multitude of cellular processes ranging from cell adhesion [14, 15] , wound healing [16] , angiogenesis [17] [18] [19] [20] , neuroprotection [18, 21] , and normal development of the heart, bone, cartilage, and brain [22] [23] [24] [25] [26] [27] . Perlecan consists of a core protein with a size between 467 kDa (humans) and over 750 kDa with the addition of three to four glycosaminoglycan (GAG) side chains [28, 29] . This multi-domain molecule is composed of five distinct regions, termed domains one to five (DI-V) (reviewed in [30] [31] [32] ). DI contains
Perlecan and the Cerebrovasculature in Disease and Stroke
The cerebral vasculature is composed of distinct types of vessels, i.e., pial arteries, arterioles, capillaries, or venules that are structurally and biochemically different, contributing to their specificity. The pial arteries consist of three main layers from inside out: the tunica intima that contains both endothelial cells and BM, surrounded by the tunica media, compromised by smooth muscle cells and the most outer part, the tunica adventitia (or connective tissue). As these vessels dive into the brain parenchyma and branch into smaller and smaller segments, they give rise to brain arteriole and capillary networks, while losing their smooth muscle (SMC) coverage but gaining more pericytes and astrocytic endfeet. All of these cells regulate and/or secrete perlecan [15, 40, [69] [70] [71] [72] [73] [74] [75] [76] . Studies investigating the effects of altered perlecan expression are contradictory, ranging from pro vs. anti-angiogenic [17, 18, 70, 77] , or associated or not with plaque and thrombotic core proteins [78] [79] [80] [81] [82] [83] [84] . The role of perlecan may depend on the model, size of the blood vessel, sex (female vs. male), and age.
Cerebrovascular diseases represent one of the top five most common causes of death in the United States [85] . As we age, our vasculature undergoes degeneration due to the accumulation of mechanical and sheer stress induced by innate fluctuations in blood pressure [86] . Arteriolosclerosis, arterial stiffness, and reduced compliance, are among the first pathologies to present, leading to altered cerebrovascular blood flow (CBF) and ECM protein metabolism, or the remodeling of ECM. Moreover, proteases known to cleave perlecan such as matrix MMPs or cathepsins [18, 61, [63] [64] [65] [66] [67] increase in cerebrovascular diseases (reviewed in [87] ). Fluctuation of perlecan expression has been reported in aging; perlecan levels in mouse brain were high at 3 months, decreased at 8 months, followed by a secondary increase at 16 months of age [88] . However, a study by Kerever et al. reported no change in perlecan expression in the subventricular zone of aged mice without comorbidity [89] . Age-related structural changes are associated with decreased CBF, contributing to cell senescence, damage, and dementia [90] [91] [92] [93] [94] [95] [96] [97] [98] . A term that encompasses cognitive decline associated with vascular change is Vascular contributions to Cognitive Impairment and Dementia or VCID. VCID is the second leading cause of dementia [99] [100] [101] behind Alzheimer's disease (AD) [102] [103] [104] [105] with many of the same vascular risk factors, such as, age, sex, hypertension [106] , atherosclerosis, and diabetes mellitus (DM) [107] [108] [109] [110] [111] [112] [113] [114] . How metabolic changes such as high glucose, high insulin, or high free fatty acid levels individually or in combination affect perlecan distribution and expression is reviewed in Table 1 . VCID etiology ranges from cerebrovascular disruption, seen in small vessel diseases of the brain, including arteriolosclerosis, and cerebral amyloid angiopathy (CAA, pathologic accumulation of amyloid beta (Aβ) protein in brain blood vessels), to the profound symptomatic damage following acute stroke. These vascular risk factors may increase BM thickness contributing to the narrowing of vascular lumen and to the disruption of BBB integrity. Changes in the BBB are dynamic, as it opens and closes multiple times within the first hours to days after ischemic injury [115] . This disrupted BBB provides a pathway for inflammatory cells that may infiltrate the brain and release additional proteases, free radicals, chemokines, and cytokines [116] [117] [118] ; further contributing to altered ECM synthesis of matrix proteins or proteolysis, splice variants, smooth muscle cell migration and proliferation [119] . The extent of the injury and remodeling in the ECM is determined by the vascular injury, loss of blood flow, resultant inflammation, and ultimately the changes in oxygen and nutrient supply to the neurons and their support cells (glia and immune cells). Atherosclerosis, a common cause and comorbidity in stroke and vascular dementia, has been linked with the distribution of ECM proteins (e.g., perlecan) in the walls of peripheral arteries. Atherosclerosis, a disease of large and medium sized arteries, develops in stages, starting with intimal hyperplasia due to lipid accumulation, followed by development of plaques and thrombosis leading to vessel occlusion (ischemic stroke) or rupture (hemorrhagic stroke) [135] [136] [137] [138] . Perlecan has been linked to lipid retention in the vasculature [83] , possibly through the LDL receptor motifs region in DII (additional studies on perlecan and atherosclerotic plaques are outlined in Table 2 ). Increased BM perlecan expression has been correlated with atherosclerotic lesions in experimental mice [79, 81] , non-human primates [139] , and in humans [80] . Interestingly, perlecan expression was found to be increased in aged human cerebral arteries but decreased as the lesion progressed [140] . Haung et al. have shown that perlecan accumulation via angII-driven mechanisms preceded the progression of atherosclerosis [81] . This suggests that perlecan accumulation may increase endothelial barrier disruption resulting in lesion formation via increased deposition of LDL. Moreover, the loss of perlecan has been associated with less atherosclerosis in early lesions of mice without effect on the lipoprotein profile [83, 141] . Also, decreased heparan sulfate and perlecan levels were detected in fully developed atherosclerotic lesions of tunica intima, derived from non-diabetic and Type 2 non-insulin-dependent diabetes mellitus patients [142] , as well as from those with carotid stenosis [143] , respectively. Hence, it is plausible that the distribution of various ECM components, especially perlecan, drives the initiation and progression of atherosclerosis. In contrast, an earlier study by Hollmann et al. reported decreased perlecan expression, associated with advancing age and severity of atherosclerosis, in both normal and atherosclerotic regions of human aorta [80] . The difference between this study and others may lie in the method of tissue preparation and perlecan detection. Additional contradictory studies show perlecan preventing atherosclerosis [84, 144, 145] . In an in vitro model, increased endothelial cell HSPG/perlecan production led to a reduction of the atherosclerotic lesions [146] .
Amyloid that accumulates within the vasculature, CAA, and brain parenchyma, forms plaques (AD) that disrupt the distribution of perlecan (Table 3 ) [147] [148] [149] , decreases the ability of SMC to bind perlecan [150] , and contributes to vascular wall weakening [147] . Modifications to the sulfate content of the specific GAG chains of perlecan were also found to be critical to the binding of amyloid [151] . In a systematic family-base genome-wide association and meta-analysis that included 15 million imputed variants from 3524 European subjects, HSPG variant rs2445130-A (p = 8 × 10 −7 ) had an increased association of AD status and onset age [152] . Furthermore, HSPGs have been found in amyloid deposits in congophilic angiopathy as well as in neuritic plaques [153] . Similarly, Lepelletier et al. reported an association in amyloid regions with high perlecan in patients with a Braak stage >2 [154] when using antibodies targeting DIV. However, a study by Verbeek et al. found agrin, and a lesser extent glypican and syndecan, to be the major HSPGs associated with amyloid, whereas perlecan was not found in hippocampal nor neocortical plaques when using antibodies against DI-DII and DIV [155] . The lack of perlecan staining on amyloid positive vessels of CAA patients has been reported as well [156] . These observations suggest the possibility that the pathologic absence of perlecan/DV contributes to, and/or is the result of cerebrovascular Aβ accumulation. Functionally, treatment with a recombinant DV of perlecan has been demonstrated to block the deleterious effects of amyloid on brain endothelial cells [17] via α5β1 integrin receptor, a key angiogenesis receptor, downregulated after brain development, and only to be upregulated in response to ischemic brain injury [157] . The role of perlecan in amyloid accumulation and clearance may be intricately regulated by cell types, vary among species, and perlecan domain dependent. Stroke results from the disruption of blood flow to the brain due to the narrowing or occlusion of a vessel (ischemic) or to the weakening of the vessel wall (hemorrhagic). Perlecan was found to be lower in non-human primate models of focal cerebral ischemia [63, 169] , whereas DV has been demonstrated to increase in rodent models of stroke (endothelin-1 and tandem common carotid artery occlusion and distal middle cerebral artery occlusion) [18] . The therapeutic potential of recombinant DV after ischemic stroke has been demonstrated by us and others [18, 40] . Correspondingly, the lack of perlecan, when using hypomorphs, Col2a1-Hspg2 TG/− and Hspg2 −/− mice, was associated with larger infarcts as well as worse functional outcomes after MCAo and decreased neurogenesis, respectively [18, 40] . Increased perlecan expression was found following traumatic brain injury in mice [75] as well as in human samples from patients with brain arteriovenous malformation [170] . Similarly, Nugent el al. showed increased thrombotic occlusion rates in perlecan-deficient endothelial cells in a porcine carotid artery injury model [51] , not surprisingly as perlecan antithrombotic/anticoagulant studies have shown perlecan directly binding to anti-thrombin III [171] .
Hypertension is an important risk factor for stroke and vascular dementia and can occur at any age as well as in pregnancy. Vascular remodeling of peripheral and cerebral blood vessels is a common feature of hypertension that has been linked to changes in perlecan (Table 4 ). Various studies have shown that increased expression and accumulation of collagen IV and elastin in peripheral and cerebral arteries lead to arterial stiffness. However, only a small number of investigators have studied the expression of perlecan in various models of hypertension. McGuire and colleagues were the first to report increased expression of perlecan in the aorta of spontaneously hypertensive rats (SHR), a model of essential hypertension [172] . This finding was corroborated in the aorta of hypertensive rats, induced by high salt diet [173] . Nonaka et al. reported reduced endothelium-dependent relaxation through lower endothelial nitric oxide synthase (eNOS) expression in aortas of perlecan-deficient mice and when perlecan is knocked-down in human aortic endothelial cells [42] , suggesting that perlecan may play a role in vasodilation. Furthermore, angII and Western diet have been reported to increase level of perlecan in biglycan deficient mice [82] . Haung et al. [81] showed that perlecan accumulation, via angII-mediated mechanisms, precedes the progression of atherosclerosis, suggesting that perlecan accumulation may facilitate endothelial barrier disruption, resulting in an increased deposition of LDL, the hallmark of atherosclerotic lesion formation. However, no change was detected in perlecan expression in a coarctation of abdominal aorta model of hypertension in rats [174] . In pregnant women, an association was found between increased plasma concentration of perlecan and early onset of gestational hypertension [175] . The authors attributed their findings to impaired microvascular perfusion leading to the degradation of glycocalyx of the kidneys. Likewise, early preeclampsia with or without HELLP (hemolysis, elevated liver enzymes, and a low platelet count) syndrome was associated with an increased placental perlecan expression that showed a positive correlation with maternal vascular malperfusion [176] . In contrast, the findings by Guo et al. showed decreased perlecan concentration in urine when compared the gestational hypertension group with controls, indicating glomerular filtration barrier injury and renal dysfunction [177] . Collectively, these observations paint a complex and underexplored role for perlecan in hypertension in the cerebrovasculature and beyond. ↓ perlecan (MP4) during placental maturation ↑ perlecan in early pregnancy loss and in preeclampsia without HELLP ↓ perlecan in late preeclampsia [176] Abbreviations. ↑: increase; ↓: decrease; −: no change; HELLP: hemolysis, elevated liver enzymes, and a low platelet count; n. sp.: not specified; SHRSP: spontaneously hypertensive stroke prone rats; wk: week.
Conclusions
Besides aging, atherosclerosis, hypertension, and diabetes are cerebrovascular risk factors for VCID, dementia and stroke, making it difficult to tease out the underlying mechanisms of cognitive decline. In addition, changes in perlecan expression and distribution in response to VCID appears to be injury, risk factor, location, sex, age, and perlecan domain dependent. Overall, great effort has been made in recent decades in understanding the role of perlecan in VCID. While recombinant perlecan DV, in mice and rats, has been found to be angiogenic, neuroprotective, and neuroreparative [17] [18] [19] 68, 157, [178] [179] [180] , new studies are warranted to address the role of perlecan and its domains in health and in combination with cerebrovascular risk factors.
